Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Blood - 9 Mar 2017

Duncavage Eric J, Uy Geoffrey L, Petti Allegra A, Miller Christopher A, Lee Yi-Shan, Tandon Bevan, Gao Feng, Fronick Catrina C, O'Laughlin Michelle, Fulton Robert S, Wilson Richard K, Jacoby Meagan A, Cashen Amanda F, Wartman Lukas D, Walter Matthew J, Westervelt Peter, Link Daniel C, DiPersio John F, Ley Timothy J, Welch John S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Azacitidine
Share to Blood Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Neoplasm Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28082444
DOI: 10.1182/blood-2016-10-745273
PMCID: PMC5345736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.PMID 28082444Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.Semantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read ↗

Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission.Semantic proximity Read ↗

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.Semantic proximity Read ↗

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.Semantic proximity Read ↗

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesSemantic proximity Read ↗

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.